



Design Therapeutics, Inc
6005 Hidden Valley Road
Suite 110
Carlsbad, CA 92011

June 20, 2023

Jennifer Farmer, MS
Chief Executive Officer
Friedreich Ataxia Research Alliance
533 West Uwchlan Avenue
Downingtown, PA 19335

Dear Jen,

Design Therapeutics would like to express our deep appreciation to people living with Friedreich's ataxia (FA) and other members of the FA community for their unflagging support of and commitment to our DT-216 development program.

Since the commencement of the DT-216 Phase 1 studies last year, those who volunteered to participate in these studies have shown amazing strength, patience, and courage while traveling to the study sites and performing a rigorous schedule of study assessments.

Conducting Phase 1 studies often requires adjusting plans in real time. We understand that these adjustments can be frustrating for everyone, and deeply appreciate the flexibility and nimbleness that so many in the FA community have demonstrated.

The DT-216 Multiple Ascending Dose (MAD) study started in the 4th quarter of 2022 and is ongoing. We are grateful to the potential participants who wait in stand-by mode while we determine the total number of participants in the MAD study.

The DT-216 development program benefits greatly from the generosity, patience, courage, and partnership of the FA community. Once again, we are so grateful to you and look forward to continuing this journey together.

Sincerely,

A handwritten signature in black ink that reads 'Jae Kim'.

Jae B. Kim MD
Chief Medical Officer
Design Therapeutics

A handwritten signature in black ink that reads 'Samuel M. Moskowitz MD'.

Samuel M. Moskowitz MD
Vice President, Clinical Development
Design Therapeutics